Prohibitin, a potential tumor suppressor, is known to induce growth suppression and repress E2F-mediated transcription. These growth regulatory functions of prohibitin require a physical interaction with the Rb protein. We now ®nd that prohibitin protects cells from apoptosis mediated by camptothecin, a topoisomerase I inhibitor. Camptothecin treatment of Ramos B cells leads to the degradation of Rb protein and phosphorylation of its family members, p107 and p130. This correlates with an increase in the levels of cyclin E as well as the kinase activity associated with it. Inactivation of Rb leads to the dissociation and release of free E2F. We ®nd also that E2F activity is induced upon camptothecin treatment, but this increase is absent in prohibitin overexpressing cells. It thus appears that prohibitin may be inhibiting apoptosis by downregulating E2F activity when Rb family members are inactive.
Introduction
The E2F transcription factors play a major role in regulating the proliferation, dierentiation and apoptosis of mammalian cells. There are six E2F family members, of which only ®ve have transactivation domains; they along with their binding partners DP1 or DP2 induce genes necessary for S phase entry as well as DNA synthesis, promoting cell proliferation (reviewed in Harbour and Dean, 2000) . The transcriptional activity of the E2Fs is modulated mainly by the Rb family of proteins. Rb binds to and represses E2Fs 1, 2, and 3; p107 and p130 regulate E2F4 and E2F5. It is the functional hypo-phosphorylated form of Rb that binds and suppresses E2F activity, along with co-repressors like histone deacetylase 1 (HDAC1) and CtBP, as well as chromatin remodeling proteins like Brg1 (Brehm et al., 1998; Luo et al., 1998; Magnaghi-Jaulin et al., 1998) . A cascade of sequential phosphorylation events mediated by cyclincdk complexes leads to the inactivation of Rb, resulting in the release of free E2F, permitting S phase entry (Knudsen and Wang, 1996) .
In addition to regulating cell cycle progression, E2F1 has also been shown to promote apoptosis in several experimental systems (reviewed in Phillips and Vousden, 2001 ). Overexpression of E2F1 promotes premature S phase entry and apoptosis in Rat-1 ®broblasts, with serum starved cells being particularly sensitive to death (Shan and Lee, 1994) . Studies in knockout mice also support a role for E2F1 in apoptosis (Hunt et al., 1997) . The dissection of the pathways mediating E2F1 induced apoptosis has revealed that at least two dierent mechanisms exist: a p53 dependent pathway and a p53 independent pathway. The p53-dependent pathway is mediated by transcriptional induction of the human INK4A locus (Bates et al., 1998) . Accumulation of the p14ARF protein leads to increased levels of p53, because p14ARF binds to the MDM2/p53 complex and inhibits MDM2 mediated degradation of p53. Though it has been suggested that p53 independent apoptosis by E2F1 does not involve its transcriptional activation domain (Hseih et al., 1997) , the p53 homologue p73 has been shown to be a transcriptional target of E2F1 and shown to be a mediator of p53 independent apoptosis Lissy et al., 2000) . Thus, transcriptional activation of dierent target genes by E2F1 is a feature of both the p53 dependent and independent apoptotic pathways.
Beyond the classic Rb/E2F/DP1 interaction, other cellular proteins also bind to and regulate E2F function. Cyclin A-cdk2 kinase has been found to contact a region amino-terminal to the DNA binding domain leading to the phosphorylation of E2F1 and its eventual degradation (Xu et al., 1994; Krek et al., 1995; Kitagawa et al., 1995) . In addition, MDM2 has been reported to bind the transactivation domain and stimulate E2F activity while repressing p53 (Martin et al., 1995) . A recently identi®ed mechanism of regulation of E2F1 is via acetylation on lysine residues. pCAF, a p300/CBP associated protein, acetylates E2F1 and augments DNA binding, protein half-life and transcriptional activity (Martinez-Balbas et al., 2000).
We have shown recently that a protein named prohibitin (Phb) binds and represses all the ®ve transcriptionally active E2Fs (Wang et al., 1999a) . Prohibitin co-immunoprecipitates with both Rb and E2F1, and contacts each protein using dierent domains. Certain signaling cascades such as IgM stimulation of B cells reverses prohibitin-mediated repression of E2F1; Rb remains inert to this stimulus (Wang et al., 1999b) . It had been shown earlier that microinjection of antisense oligonucleotides against prohibitin promotes entry into S phase (Nuell et al., 1991; Jupe et al., 1995) . Supporting this observation, we ®nd that colony formation of various breast cancer cell lines is repressed by prohibitin. Immunocytochemical studies indicate that prohibitin is highly expressed in neoplastic foci of various tumor types (Coates et al., 2001) . It has been suggested that prohibitin associates with the IgM receptor in murine B lymphocytes (Terashima et al., 1994) . In yeast, however, it has been found that prohibitin might associate with the mitochondrial inner membrane (Coates et al., 2001; Berger and Yae, 1998; Steglich et al., 1999; Nijtmans et al., 2000) . Most recently, prohibitin-2 was found to associate with and repress the nuclear estrogen receptor. Also known as REA for repressor of estrogen activity, this protein is unique in its ability to selectively bind the unliganded estrogen receptor and to maintain it in a repressed state (Delage-Mourroux et al., 2000; Montano et al., 1999) .
Given the growth suppressive function of prohibitin and its ability to repress E2F-mediated transcription, we set out to explore whether prohibitin also aects the apoptotic process. We show that the expression of prohibitin can protect cells from death induced by the chemotherapeutic drug camptothecin. While Rb family members are functionally inactivated during drug treatment, prohibitin levels are elevated. We therefore speculate that prohibitin provides another level of E2F regulation in situations where speci®c apoptotic stimuli upset the balance between survival and death.
Results

Prohibitin protects cells from camptothecin induced apoptosis
Since E2F1 has been demonstrated to be a proapoptotic transcription factor, we decided to examine whether prohibitin, a known repressor of E2F induced transcription, aected the response of cells to apoptotic stimuli. As an initial step, the B cell lymphoma line Ramos stably over-expressing prohibitin was generated and its response to four chemotherapeutic drugs was compared with that of the parental cells. The overexpression of prohibitin was checked by Western blotting, and the stably transfected cells contained about ®vefold more prohibitin than the parental cells. Cells were treated with tamoxifen (an estrogen mimic), 5-¯uoro-uracil (a thymidylate synthetase inhibitor), paclitaxel (a microtuble depolymerization inhibitor), or camptothecin (a topoisomerase I inhibitor). A range of drug doses and treatment times were tested so that a signi®cant number of cells underwent apoptosis. The level of apoptosis was assessed by annexin staining, followed by¯ow cytometry. As shown in Table 1 , the overexpression of prohibitin did not signi®cantly alter the number of annexin positive cells upon treatment with tamoxifen, 5-¯uoro-uracil, or paclitaxel. However, upon treatment with 15 mM camptothecin, the prohibitin over-expressing cells showed reduced levels of apoptosis compared to the parental Ramos line; 26% of the prohibitin over-expressing cells underwent apoptosis in response to camptothecin compared to 49% of the parental cells. These results were con®rmed by repeating the annexin staining and using¯uores-cence microscopy to count the number of annexin positive cells in situ. These ®ndings suggest that prohibitin can protect cells from camptothecin induced apoptosis.
To assess whether prohibitin aected receptor mediated cell death, the same two cell lines were treated with an anti-Fas antibody for 2 h. The two cell lines had similar levels of annexin positive cells when analysed by¯ow cytometry (Table 1) suggesting that prohibitin had no detectable eect on Fas mediated apoptosis. Thus, prohibitin provides speci®c protection to B cells from death induced by camptothecin, and does not serve as a general inhibitor of apoptosis.
Additional studies were done using human breast carcinoma cell lines that express dierent levels of endogenous prohibitin protein. We have shown previously by Western blotting that the cell line ZR751 has low levels of prohibitin protein, T47D an intermediate level, and BT549 a high level, relative to each other. These diering levels of prohibitin have an eect on E2F activity: those cells which contain more prohibitin have lower E2F activity than those with less prohibitin, as determined by transient transfection (Wang et al., 1999a) . When we measured the amount of apoptosis after treating these cells with 15 mM camptothecin, it was found that the cells with the higher amount of prohibitin, T47D and BT549, were protected from death compared to the ZR751 line, expressing less prohibitin (Table 2 ). This result mirrors our ®ndings with the Ramos cells, where cells overexpressing prohibitin showed a reduced amount of apoptosis. The response of these breast cancer cell lines to receptor-mediated apoptosis was also assessed. The ZR751 and BT549 cells were treated with 50 mg/ml of anti-TNFa for 6 h. The two cell lines exhibited similar levels of apoptosis as measured by counting the number of annexin positive cells in situ (Table 2) . We conclude from these collective results that prohibitin does not aect receptor-mediated death by either the Fas or TNF pathways, but can confer protection to camptothecin in dierent cell lines. The potential mechanisms involved in this protection were next explored.
Rb family members are inactivated during camptothecin induced death
Because we have shown previously that prohibitin can both interact with Rb family members and repress E2F transcriptional activity, we next examined how drug treatment aected the levels of Rb protein. For this purpose, whole cell extracts were prepared from Ramos cells treated with tamoxifen, camptothecin, 5-¯uoro-uracil, or paclitaxel for 5 h and used for Western blotting using two dierent Rb antibodies. When an antibody speci®c for an internal region of Rb (amino acids 300 to 380) was used, a faster migrating, truncated species of Rb was evident ( Figure 1a ). When an antibody speci®c for the C-terminal region of Rb was used, no Rb could be detected after 5 h of camptothecin treatment (Figure 1a ). Other studies have shown that a 5 kD portion of Rb at its Cterminus is cleaved during apoptosis induced by TNFa and other agents (Janicke et al., 1996; Chen et al., 1997) . It appears that Rb might be undergoing caspase mediated degradation as a result of camptothecin treatment.
In order to understand the kinetics of camptothecin induced degradation of Rb, whole cell extracts were prepared from Ramos cells treated with the drug for 0, 1, 3, 5, or 8 h and examined by Western blotting. We found that Rb levels declined, to undetectable levels, after 5 h of treatment ( Figure 1b) .
Because we observed a degradation of Rb protein, we next examined whether the levels of the Rb family members p107 and p130 were aected in a similar fashion. Western blots of the same set of extracts showed that while Rb was degraded within 5 h of treatment, p107 and p130 levels were not aected signi®cantly; but interestingly, they were shifted to a hyper-phosphorylated form ( Figure 1b) . We conclude from these results that camptothecin treatment inactivates the Rb family members, by either directly causing protein degradation, as in the case of Rb or by promoting phosphorylation of p107 and p130.
Cyclin E levels rise in response to camptothecin
Since we observed the hyper-phosphorylation of p107 and p130 in response to camptothecin, we next checked whether levels of cyclin D and cyclin E, which are Human breast carcinoma cell lines ZR751, which expresses low levels of endogenous prohibitin protein, T47D, which expresses an intermediate level, and BT549, which expresses high levels of endogenous prohibitin protein, were treated with camptothecin or TNFa as indicated. The number of dying cells was assessed by annexin staining followed by in situ¯ourescence microscopy. ND=not determined known to regulate these proteins by phosphorylation, were changed. The extracts used in the previous experiments were utilized again for Western blot analysis. We found that cyclin D1 levels remained constant in extracts treated with tamoxifen, camptothecin, 5-¯uoro-uracil, or paclitaxel for 5 h compared to untreated cells (Figure 2a) . However, when the same blot was stripped and probed for cyclin E, we found that its level increased signi®cantly in the presence of camptothecin compared to the other drugs (Figure 2a ). To assess whether the changes in cyclin levels followed the same kinetics of phosphorylation observed in p107 and p130, Western blotting was performed on the Ramos extracts treated with camptothecin for 0, 1, 3, 5, or 8 h. While we did not observe a change in cyclin D1 protein levels, levels of cyclin E dramatically increased, following the same time kinetics as the changes seen in phosphorylation (Figure 2b ). The changes seen in cyclin E corresponded with a slight increase in its kinase activity using histone H1 as a substrate in an in vitro kinase assay of camptothecin treated extracts (Figure 2c ). Northern analysis of total cellular RNA prepared from camptothecin treated Ramos cells showed that the amount of cyclin E message increased by 5 h of drug treatment (Figure 2d ) suggesting that the increase in cyclin E levels happens at the transcriptional level.
To ensure that the observed changes in cyclin levels were not due to dierences in the cell cycle pro®les of the asynchronous cell populations used, the camptothecin time course was repeated on cells that had been serum starved for 48 h. The Western blotting results were similar as observed for cycling cells (data not shown). Thus, camptothecin appears to induce cyclin E levels speci®cally.
E2F loses association with Rb, p107 and p130
Given the functional inactivation we observed for Rb family members, we next explored the consequences of this inactivation on their binding to E2F. First, a gelshift assay (EMSA) was performed using a radiolabeled probe derived from the adenovirus E2 promoter containing E2F binding sites. This probe was incubated with extracts prepared from cells treated with tamoxifen, camptothecin, 5-¯uoro-uracil, or paclitaxel. When the bound complexes were resolved by non-denaturing gel electrophoresis, we observed an increase in the amount of unbound, free E2F in camptothecin treated cell extracts, but no changes in the extracts after treatment with the other drugs (Figure 3a) . The extracts from cells treated with camptothecin for dierent time periods were also examined by gel-shift analysis. We found an increase in the free form of E2F appearing 5 h after treatment and persisting for at least 8 h (Figure 3b ). This increase coincides with the functional inactivation of Rb family members.
To assess whether the Ramos cells over-expressing prohibitin also released free E2F, extracts from cells treated with camptothecin for 0, 1, 3, 5, or 8 h were used for gel shift experiments. We found that the prohibitin over-expressing cells exhibited an increase in the free form of E2F, similar to that seen in the parental cell lines (Figure 3c ). Thus, inactivation of Rb family members results in release of free E2F in both cell lines. Antibody supershift assays were used to show the speci®ty of the identi®ed complexes (Figure 3d) .
To evaluate the amount of E2F interacting with each Rb family member, co-immunoprecipitation followed by gel-shift was performed. The extracts from Ramos cells treated with camptothecin for dierent Figure 2 Elevated cyclin E protein level and activity in response to camptothecin treatment. (a) Whole cell extracts from drug treated Ramos extracts were prepared as in Figure 1 and a Western was performed for cyclin D1. The same membrane was stripped and re-probed for cyclin E. (b) Induction of cyclin E protein levels upon camptothecin treatment for 0, 1, 3, 5, or 8 h. The same blot was stripped and re-probed for cyclin D1. (c) Cyclin E kinase assay. Whole cell extracts from Ramos cells treated with camptothecin for the time points indicated were immunoprecipitated with a cyclin E antibody. Cyclin E associated kinase activity was assessed in vitro using histone H1 as a substrate. (d) Cyclin E Northern blot. Total cellular RNA was prepared from Ramos cells treated with camptothecin for the time points indicated and the level of cyclin E message was measured E2F regulators in camptothecin-induced apoptosis G Fusaro et al time points were incubated with antibody for Rb, p107, or p130. The bound complexes were recovered on Protein A sepharose beads, washed, disassociated by incubation in sodium deoxycholate, and resolved on a polyacrylamide gel. In untreated cells, E2F was found to be present in complexes with all three Rb family members. After 5 h of camptothecin treatment, however, the Rb/E2F interaction is completely lost (Figure 4a ). E2F remains bound to p107 and p130 for a longer period of time compared to Rb, but the overall amount of bound complex is reduced over the time course of treatment (Figure 4b, c) . From these Figure 1 . A gel shift assay was performed using 10 mg of extract incubated with a 32 P-labeled probe containing E2F binding sites. The bound complexes were resolved on a polyacrylamide gel and visualized by autoradiography. Free E2F refers to E2F/DP complexes no longer associated with Rb family proteins. (b) Gel shift assay using 10 mg of Ramos whole cell extracts prepared from cells treated with 15 mM camptothecin for the time points indicated. (c) Gel shift assay using 10 mg of extract from Ramos cells stably overexpressing prohibitin and treated with 15 mM camptothecin for the time points indicated. (d). Antibody supershift assay. Extracts were pre-incubated with 4 ml of the indicated antibodies for 4 h prior to addition of probe mixture. c-Myc antibody was used as a negative control results we infer that camptothecin leads to the disruption of the interaction between E2F and all three Rb family members.
Prohibitin prevents E2F transactivaton after camptothecin treatment
Because of the inhibitory eect of prohibitin on camptothecin induced death, we next examined whether prohibitin protein levels were altered upon camptothecin treatment. Prohibitin levels in whole cell extracts made from Ramos cells treated with 15 mM camptothecin for 0, 1, 3, 5 or 8 h were examined by Western blot analysis. In contrast to the degradation observed for Rb, prohibitin levels signi®cantly increased after 5 h of drug treatment (Figure 5a ). This increase is not occurring at the transcriptional level, because the level of prohibitin message remained unchanged during this treatment (Figure 5b) . At 8 h of treatment, we observed a reduction in the amount of prohibitin message This decrease is likely due to a degradation of the message. However, it remains possible that other mechanisms, such as a decrease in transcription, are causing the change.
In order to determine whether the generation of free E2F upon drug treatment resulted in increased transcriptional activity, a transient transfection was performed. Ramos cells were transfected with 10 mg of a construct containing E2F binding sites fused to a CAT reporter. When these cells were treated with camptothecin for 5 h, a dramatic increase in CAT activity was seen compared to untreated cells ( Figure  5c , columns 1 and 2). Interestingly, when this same experiment was repeated using Ramos cells stably overexpressing prohibitin, the amount of CAT activity was reduced to almost basal level in the presence of camptothecin (Figure 5c , columns 3 and 4). We infer from these results that the increase in E2F transcriptional activity in response to this drug is ablated by the presence of prohibitin. Prohibitin may thus function to protect cells from camptothecin induced death by repressing E2F activity.
Discussion
Many cell cycle regulatory proteins have the dual function of regulating cell proliferation as well as apoptosis (reviewed in Blagosklonny, 1999) . The E2F transcription factors, especially E2F1, are a prime example of this activity (reviewed in (Phillips and Vousden, 2001 ). Studies over the past few years have shown that E2F transcription factors play a signi®cant role in promoting the G1/S transition (reviewed in Harbour and Dean, 2000) ; interestingly, E2F1 over-expression also induces apoptosis under many circumstances (Shan and Lee, 1994) . It became apparent that not only E2F1, but its main negative regulator, Rb, also responds to proliferative as well as apoptotic signals (Pan et al., 1998; Morgenbesser et al., 1994) . Here we show that prohibitin, a novel regulator of E2F activity, also modulates apoptosis in response to speci®c signals.
Our current studies show that cells over-expressing prohibitin are resistant to camptothecin mediated apoptosis, but not apoptosis induced by other chemical agents. These observations are interesting in light of ®ndings from other groups showing that over-expression of E2F1 in myeloid progenitor cells leads to sensitivity to the topoisomerase II inhibitor etoposide, but not to other agents such as paclitaxel or 5-¯uoro-uracil (Nip et al., 1997) . Indeed, increased prohibitin levels had no eect on receptor-mediated apoptosis either. Thus, prohibitin is capable of speci®cally targeting certain pathways leading to apoptosis; it may be imagined that prohibitin is blocking some earlier, speci®c events rather than late, shared events common to all apoptotic pathways like disruption of mitochondrial integrity and release of cytochrome c. It is not known whether prohibitin can aect these latter events in apoptosis, but it is an interesting possibility since prohibitin has been reported to be localized in the mitochondrial membranes as well (Coates et al., 2001; Nijtmans et al., 2000; Berger and Yae, 1998; Steglich et al., 1999) . Our experiments have shown prohibitin to be present ubiquitously in the cell, including the nucleus, where it co-localizes with Rb and aects transcriptional activity of E2F (unpublished data). Given the reported mitochondrial localization of prohibitin as well as the nuclear functions attributed to it, probably it is acting at multiple levels during the apoptotic process.
Our earlier studies have shown that prohibitin is capable of repressing E2F-mediated transcription very eectively, which might suggest that prohibitin is inhibiting apoptotic pathways by repressing the transcriptional activity of E2F1. The ®nding that prohibitin is aecting only speci®c and hence early signaling pathways leading to apoptosis can be explained by the transcriptional repressive properties of prohibitin. Investigations have revealed that E2F1 induces apoptosis by one of three generalized mechanisms: (1) inhibition of anti-apoptotic pathways, especially in receptor mediated cell death (Phillips et al., 1999) ; (2) induction of pro-apoptotic genes like p73 and Apaf-1 Lissy et al., 2000; Muller et al., 2001; Moroni et al., 2001) ; and (3) stabilization of p53 levels by inducing p14ARF (Bates et al., 1998) . Gene array technology has identi®ed novel target genes for E2F1 that have pro-apoptotic function, for example apaf1, caspase 3 and caspase 7 as well. Furthermore, disruption of the E2F1 gene causes increases in T cell levels, indicative of defects during the apoptotic program in T cell development (Field et al., 1996; Yamasaki et al., 1996) . These studies strongly suggest that the transcriptional activity of E2F1 contributes to its apoptotic potential. It should be pointed out, though, that under certain circumstances, the activation domain of E2F1 is not necessary to induce apoptosis (Hseih et al., 1997) .
Overall, it appears safe to assume that E2F1 contributes to the apoptotic process by inducing multiple pro-apoptotic genes. It is possible that prohibitin may be inhibiting the apoptotic process by preventing the expression of these pro-apoptotic genes and experiments are underway to examine this possibility.
One of the intriguing observations is that all the three Rb family members are inactivated upon camptothecin treatment. It is likely that the cells are inactivating the Rb proteins to release free, transcriptionally active E2F to facilitate the apoptotic process.
The mechanisms behind the inactivation of the Rb family proteins reveal that while cyclin D levels remain stable, the level of cyclin E protein is enhanced. Interestingly, the cyclin E promoter has E2F binding sites and is regulated by the Rb-E2F pathway during cell cycle progression. Given the kinetics of Rb degradation and the induction of cyclin E, it appears that the increase in cyclin E levels could have resulted from increased E2F activity, and subsequently contributed to the phosphorylation of p107 and p130. This conclusion is drawn from the fact that Rb is already degraded before cyclin E levels are elevated.
Unlike Rb, we see no evidence that prohibitin is degraded during camptothecin induced death. Rather, prohibitin protein level increases. We have previously noted other dierences between Rb and prohibitin in response to upstream signaling molecules (Wang et al., 1999b) . For example, co-transfection of cyclin D or cyclin E with Rb ablates the ability of Rb to repress E2F, but not prohibitin. The response of Rb versus prohibitin to viral antigens such as adenoviral E1A protein also diers. It might be of signi®cance that the cells are elevating the levels of prohibitin, an E2F suppressor, that does not respond to cyclin E or protease degradation. Thus, the cells seem to elevate the levels of prohibitin which can suppress E2F activity when sucient amounts of Rb family members are not present. This could be an attempt to maintain the cells in a quiescent state to facilitate the necessary repairs and adjustments needed to recover from the apoptotic stress and thus enhance the chance of survival. Though in our experiments prohibitin was unable to confer a complete protection against apoptosis, prohibitin may tilt the balance in favor of one response versus the other.
Although our initial interest in prohibitin stemmed from its similarity to Rb in repressing E2F activity and inducing growth arrest, our subsequent observations indicate that these two proteins respond to dierent signaling cascades. We infer from the current experiments that prohibitin not only acts as a repressor of E2F activity during normal cellular conditions, but may also aid in the decision between survival and death during times of apoptotic stimulation. Our continuing studies will try to elucidate which of these mechanisms are shared by the two proteins and which are divergent. These studies might lead to a more re®ned understanding of how dierent signals feed into E2F to control both cell cycle progression and apoptosis.
Materials and methods
Cell lines, transfections and vectors
The human Ramos B cell lymphoma line and Ramos cells stably transfected with full length prohibitin (Ramos Phb) were maintained in RPMI medium with 10% FBS. The T47D human breast carcinoma cell line was maintained in DMEM medium with 10% FBS and the ZR751 and BT549 human breast carcinoma cells were maintained in RPMI with 10% FBS.
Ramos cells stably overexpressing prohibitin were generated by transfection of pCDNA3-prohibitin (12 mg per 25 ml of cells) by electroporation. Cells were incubated overnight, and the next day the cell volume was doubled. Cells were incubated for 48 h. The culture was aliquoted into six-well culture plates. Cells were selected in G418 (40 mg/ml) for 3 days. Each cell culture was then diluted in half with further selection in G418 for another 3 days. This step was then repeated. The cells were then aliquoted into 96-well plates with an equal volume of G418 added to each well and cultured for 3 days. The cells were further serially diluted until clonal cell lines were established. The clones were con®rmed by Western blot analysis. Stocks of cells were made from these lines, which were used in further experiments.
Transient transfection of Ramos cells and Ramos (Phb) cells was performed by electroporation using a Bio-Rad gene pulser at 250 V. Ten mg of E2CAT reporter plasmid was used in each transfection, along with 2 mg of a b-galactosidase expression vector as an internal control. Assays for bgalactosidase and chloramphenical acetyltransferase activity were performed using standard protocols (Wang et al., 1999a) .
Annexin staining, flow cytometry and immunofluorescence
Annexin staining was performed using the Annexin V-FITC Apoptosis Detection Kit 1 (Pharmingen) according to manufacturer's directions. Brie¯y, 500 000 cells were collected after drug or antibody treatment, washed two times with 16PBS, and resuspended in 500 ml of binding buer. Cells were incubated with 4 ml of Annexin V-FITC at room temperature for 5 min, and then analysed by¯ow cytometry or immuno¯uorescence.
For visualization by immuno¯uorescence, cells were grown on 24 well plates and stained as described above. A Nikon Eclipse TE 300 microscope was used to count representative ®elds of cells scoring positive for FITC.
For¯ow cytometry analysis, stained cells were transferred to round-bottom tubes and analysed in a FACScalibur cell sorter using the FITC emission signal detector (FL1).
Whole cell extract preparation
Extracts were prepared by hypotonic shock. Ramos cells or Ramos (Phb) were collected by centrifugation at 1500 g for 10 min. Cell pellets were washed three times with cold PBS buer. The packed cell volume was estimated, and cells were then resuspended in hypotonic buer (10 mM KCl, 10 mM HEPES, pH 7.9, 1.5 mM MgCl 2 , 0.5 mM DTT, 1 mM PMSF, 0.4 mM NaF and 0.4 mM Na 2 VO 4 ) at 1.5 times the packed cell volume. Cells were allowed to swell for 15 min at 48C. Cells were lysed by passing them 20 times through a syringe with a 22 G 1.5 needle. The lysate volume was measured, and a high salt buer (1.6 M KCl, 20 mM HEPES, pH 7.0, 0.2 mM EDTA, 0.1 mM PMSF, 1 mM DTT, 0.4 mM NaF, 0.4 mM Na 2 PO 4 and 20% glycerol) was added to 1.66 times the lysate volume. The lysates were rotated at 48C for 15 min and then ultracentrifuged at 100 000 g for 30 min at 48C. The supernatent was collected and dialyzed in dialysis buer containing 50 mM KCl, 20 mM HEPES pH 7.0, 0.1 mM EDTA, 0.1 mM PMSF, 1 mM DTT, 0.4 mM NaF, 0.4 mM Na 2 PO 4 and 10% glycerol for 30 min. The dialyzed cell extract was then spun at 15 000 r.p.m. for 10 min at 4 degrees. The supernatent was collected and stored at 7808C.
Drug and antibody treatments
Camptothecin, paclitaxel, 5-¯uoro-uracail, and tamoxifen were purchased from Sigma. Anti-Fas mouse monoclonal antibody was purchased from MBL. TNFa recombinant protein was purchased from Promega. Ramos and Ramos(Phb) cells were treated with drugs as indicated in Table  1 . BT549, T47D, and ZR751 cells were treated as indicated in Table 2 .
Western blots and antibodies
Seventy-®ve mg of the whole cell extracts described above were boiled in SDS sample loading buer and resolved on 8% polyacrylamide gels. The proteins were transferred onto nitrocellulose membranes by semidry transfer, blocked in 5% non-fat dry milk, incubated with the appropiate primary and secondary antibody, and detected by enhanced chemiluminescence assay (Amersham). The following primary antibodies were used: Rb mouse monoclonal (Oncogene Research Products Cat # OP28) speci®c for amino acids 300 to 380 of pRb; Rb rabbit polyclonal Ab (Santa Cruz Biotechnology, C15) mapping to the C-terminus of human pRB. The following antibodies were obtained from Santa Cruz: Cyclin E rabbit polyclonal (M-20); Cyclin D1 mouse monoclonal (HD11); p107 rabbit polyclonal (C-18). The Phb mouse monoclonal antibody was from NeoMarkers (Fremont, CA, USA). The p130 mouse monoclonal antibody was from Transduction Labs (R27020).
Immunoprecipitation
One hundred and ®fty mg of whole cell extract was incubated with 5 ml of antibody to Rb, p107, or p130 for 1 h at 48C. In a buer containing 20 mM HEPES, pH 7.9, 40 mM KCl, 1 mM MgCl 2 , 1 mM EGTA, 1 mM EDTA, 1 mM DTT, 1 mM NaF, 1 mM Na 3 VO 4 , 0.5% NP-40, and 3 mg/ml BSA in a ®nal volume of 100 ml. Then, 3 mg of protein A-sepharose beads were added in a 100 ml buer volume and incubated for an additional 1 h at 48C. The beads were washed ®ve times with 700 ml of the same buer. After washing, the beads were treated with 9 ml of 0.8% sodium deoxycholate made up in the same buer to release the protein bound to the beads. The supernatent was treated with 1 ml of NP-40 and then used in subsequent gel shift analysis.
Gel-shift assay (EMSA)
An EcoRI/HindIII fragment of the adenovirus E2 promoter containing two E2F binding sites (TTTCGCGC) was end labeled with a 32 P-dATP by Klenow enzyme and used as a probe. The supernatents from the immunoprecipitation assays used above or 8 mg of whole cell extract was incubated with 0.2 ng of labeled E2F probe in a shift buer made up of 20 mM HEPES, pH 7.9, 40 mM KCl, 1 mM MgCl 2 , 1 mM EGTA, 1 mM EDTA, 1 mM DTT, 1 mM NaF, 1 mM Na 3 VO 4 , 0.5% NP-40, 1 mg/ml of salmon sperm DNA and 10 mg/ml of BSA. After incubation at room temperature for 15 min, the reactions were separated on a 4% polyacrylamide gel in 0.25% TBE buer at 300 V for 3 h at 48C. The gel was then dried and the bands were detected by autoradiography. For supershift assays, the extract was ®rst pre-incubated with 4 ml of antibody in 16shift buer without NP-40, salmon sperm DNA, or BSA for 2 h on ice. The probe mixture was then added as above. The following antibodies were purchased from Santa Cruz: c-Myc mouse monoclonal (9E10), E2F1 rabbit polyclonal (C-20), and DP-1 rabbit polyclonal (K-20).
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In vitro kinase assay
Immunoprecipitation using the appropiate antibody was performed as described above. After the ®fth wash, two additional washes were done in kinase assay buer (50 mM Tris, pH 7.4, 10 mM MgCl 2 , and 1 mM DTT). The reactions were performed on the washed beads in a ®nal volume of 30 ml containing kinase assay buer, 1.25 ml of 2 mM ATP, 4 mg histone H1 substrate (Sigma) and 10 mCi of g-32 P-ATP. Reactions were incubated for 15 min at 378C, vortexed, and boiled. The boiled supernatent was separated on a 10% SDS ± PAGE gel. Histone H1 phosphorylation was assessed by autoradiography.
Northern blots
Total cellular RNA was prepared from asynchronously growing Ramos cells using the Total RNA Isolation System 1 (Promega) according to manufacturer's protocol. Twenty mg of total RNA was run on a 1% agarose formaldehyde gel and then stained.
To prepare the gel for transfer, it was ®rst de-purinated in 0.25 M HCl for 10 min. It was then incubated in 50 mM NaOH for 25 min at room temperature, and then in 200 mM NaOAc, pH 4, for 2620 min at room temperature. The gel was blotted overnight in 106SSC on a MAGNA nylon membrane (Osmonics). The membrane was then rinsed in 26SSC and UV crosslinked (Stratalinker).
The membrane was incubated in pre-hybridization buer (56SSPE, 50% formamide, 0.5% SDS, 100 mg/ml denatured ssDNA, and 56Denhardt's solution) at 428C for 1 h. The membrane was incubated overnight in hybridization buer (50% formamide, 56Denhardt's solution, 56SSPE, 0.5% SDS, 100 mg/ml denatured ssDNA, 10% Dextran and denatured radiolabled probe).
The probe was prepared using the Prime-a-Gene Labeling Kit (Promega) with up to 25 ng of DNA and 50 mCi of a-32 PdATP and 50 mCi of a-32 P-dCTP and then puri®ed. The prohibitin probe was prepared from a BamHI/XbaI digestion of pCDNA3.Phb encoding full-length prohibitin of rat origin. The cyclin E probe was prepared from an EcoRI digestion of pCMV cyclin E of human origin.
The membrane was then washed for 2615 min at 378C with each of the following wash buers: Wash Buer 1 (56SSPE, 1% SDS); Wash Buer 2 (16SSPE, 1% SDS); Wash Buer 3 (0.16SSPE, 1% SDS). Bands were visualized by autoradiography.
